NRx Pharmaceuticals announced that advice from regulatory counsel, which includes former senior officials from the Food and Drug Administration, supports filing two New Drug Applications in 2024: an application for Accelerated Approval for NRX-101 to treat bipolar depression in patients with akathisia and an application for approval of NRX-100 for treatment of suicidal depression. Gaining these approvals has the potential to yield more than $150 in revenue per NRXP share in the near term, at current share count.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRXP:
- NRX Pharmaceuticals Faces Agreement Termination, Eyes Accelerated Approval
- NRx Pharmaceuticals’ NRX-101 eeduces suicidality in bipolar depression trial
- NRX Pharmaceuticals Eyes $30M Refinancing and Funding Deal
- NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update
- NRx Pharmaceuticals reports final trial results of NRX-101